[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-iv-breast-cancer-ajcc-v6-and-v7\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-iv-breast-cancer-ajcc-v6-and-v7":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,101,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100464928","collecting-blood-samples-from-patients-with-and-without-cancer-to-evaluate-tests-for-early-cancer-detection-100464928",false,"NCT05334069","Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","Blinded Reference Set for Multicancer Early Detection Blood Tests","Inclusion Criteria:\n\n* Participants with a cancer diagnosis: Documentation of disease:\n\n  * Histologic documentation: Histologically confirmed diagnosis of invasive cancer\n  * Stage: Stage I-IV per American Joint Committee on Cancer (AJCC) 7th edition, with the exception of patients with leukemia, lymphoma, and multiple myeloma\n\n    * For leukemia: Type (chronic lymphocytic leukemia \\[CLL\\], chronic myeloid leukemia \\[CML\\], acute lymphoblastic lymphoma \\[ALL\\], acute myeloid leukemia \\[AML\\])\n    * For lymphoma: Stage I-IV based on Ann Arbor staging\n    * For multiple myeloma: Stage I, II, III based on Revised International Staging System (RISS)\n  * One of the following tumor types:\n\n    * Colorectal\n    * Bladder\n    * Head and neck\n    * Hepatobiliary\n    * Lung\n    * Lymphoma\n    * Leukemia\n    * Ovary \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Pancreas \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Multiple myeloma\n    * Gastric, esophageal or gastroesophageal\n    * Breast\n    * Thyroid\n    * Kidney\n\n      * For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Endometrium\n    * Prostate\n    * Melanoma\n\n      \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Sarcoma\n* Participants with a cancer diagnosis: No prior definitive systemic or local anti-cancer intervention\n* Participants with a cancer diagnosis: Age \\>= 40 and =\\\u003C 75\n* Participants with a cancer diagnosis: No known current pregnancy by self-report\n* Participants with a cancer diagnosis: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis\n* Participants with a cancer diagnosis: Willingness to provide blood samples for research use\n* Participants with a cancer diagnosis: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants with a cancer diagnosis: No history of organ transplantation\n* Participants with a cancer diagnosis: Ability to read and comprehend English or Spanish\n\n  \\* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages\n* Participants without a cancer diagnosis and without suspicion of cancer: Age \\>= 40 and =\\\u003C 75\n* Participants without a cancer diagnosis and without suspicion of cancer: No known current pregnancy by self-report\n* Participants without a cancer diagnosis and without suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers)\n* Participants without a cancer diagnosis and without suspicion of cancer: Willingness to provide blood samples for research use\n* Participants without a cancer diagnosis and without suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants without a cancer diagnosis and without suspicion of cancer: No history of organ transplantation\n* Participants without a cancer diagnosis and without suspicion of cancer: Ability to read and comprehend English or Spanish\n\n  \\* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages\n* Participants with a high suspicion of cancer: High suspicion of ovarian cancer, pancreatic cancer, kidney cancer, or melanoma by clinical and\u002For radiological assessment, with plans for histologic or cytologic confirmation within 28 days after study blood draw\n\n  \\* Examples of highly suspicious cases include: elevated CA125 and abnormal transvaginal ultrasound, suspicious renal or pancreatic mass on imaging, suspicious cutaneous lesion concerning for melanoma\n* Participants with a high suspicion of cancer: Central review of radiology reports and\u002For clinical documentation conducted by study chairs\n* Participants with a high suspicion of cancer: Age \\>= 40 and =\\\u003C 75\n* Participants with a high suspicion of cancer: No known current pregnancy by self-report\n* Participants with a high suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis\n* Participants with a high suspicion of cancer: Willingness to provide blood samples for research use\n* Participants with a high suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants with a high suspicion of cancer: No history or organ transplantation\n* Participants with a high suspicion of cancer: Ability to read and comprehend English or Spanish \\* Eligibility is restricted to individuals who can comprehend and read English and Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages",true,"ALL","40 Years","75 Years",{"count":21,"type":22},2000,"ESTIMATED","OBSERVATIONAL","This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Ann Arbor Stage I Lymphoma","Ann Arbor Stage II Lymphoma","Ann Arbor Stage III Lymphoma","Ann Arbor Stage IV Lymphoma","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia","Gastroesophageal Junction Adenocarcinoma","Head and Neck Carcinoma","Hematopoietic and Lymphoid Cell Neoplasm","Invasive Breast Carcinoma","Kidney Carcinoma","Malignant Hepatobiliary Neoplasm","Malignant Solid Neoplasm","Melanoma","Muscle-Invasive Bladder Carcinoma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma","RISS Stage III Plasma Cell Myeloma","Sarcoma","Stage I Bladder Cancer AJCC v6 and v7","Stage I Breast Cancer AJCC v7","Stage I Colorectal Cancer AJCC v6 and v7","Stage I Esophageal Cancer AJCC V7","Stage I Gastric Cancer AJCC V7","Stage I Lung Cancer AJCC v7","Stage I Ovarian Cancer AJCC v6 and v7","Stage I Pancreatic Cancer AJCC v6 and v7","Stage I Prostate Cancer AJCC v7","Stage I Uterine Corpus Cancer AJCC v7","Stage II Bladder Cancer AJCC v6 and v7","Stage II Breast Cancer AJCC v6 and v7","Stage II Colorectal Cancer AJCC v7","Stage II Esophageal Cancer AJCC v7","Stage II Gastric Cancer AJCC v7","Stage II Lung Cancer AJCC v7","Stage II Ovarian Cancer AJCC v6 and v7","Stage II Pancreatic Cancer AJCC v6 and v7","Stage II Prostate Cancer AJCC v7","Stage II Uterine Corpus Cancer AJCC v7","Stage III Bladder Cancer AJCC v6 and v7","Stage III Breast Cancer AJCC v7","Stage III Colorectal Cancer AJCC v7","Stage III Esophageal Cancer AJCC v7","Stage III Gastric Cancer AJCC v7","Stage III Lung Cancer AJCC v7","Stage III Ovarian Cancer AJCC v6 and v7","Stage III Pancreatic Cancer AJCC v6 and v7","Stage III Prostate Cancer AJCC v7","Stage III Uterine Corpus Cancer AJCC v7","Stage IV Bladder Cancer AJCC v7","Stage IV Breast Cancer AJCC v6 and v7","Stage IV Colorectal Cancer AJCC v7","Stage IV Esophageal Cancer AJCC v7","Stage IV Gastric Cancer AJCC v7","Stage IV Lung Cancer AJCC v7","Stage IV Ovarian Cancer AJCC v6 and v7","Stage IV Pancreatic Cancer AJCC v6 and v7","Stage IV Prostate Cancer AJCC v7","Stage IV Uterine Corpus Cancer AJCC v7","Thyroid Gland Carcinoma","RECRUITING","2026-07-01",{"date":91,"type":92},"2026-07-02","ACTUAL",{"date":94,"type":92},"2022-08-18",{"date":96,"type":22},"2027-02-28",{"name":98,"class":99},"Alliance for Clinical Trials in Oncology","OTHER",745,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100402553","phase-1-a-vaccine-mv-s-nap-for-the-treatment-of-patients-with-invasive-metastatic-breast-cancer-100402553","NCT04521764","A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer","Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer","Inclusion Criteria:\n\n* Age \\>= 18 years\n* COHORT 1 ONLY: Pathologically confirmed invasive breast adenocarcinoma with documented estrogen receptor (ER)\u002Fprogesterone receptor (PR) \u002FHER2 status and radiographic evidence of distant metastatic disease\n* COHORTS 2 \\& 3 ONLY: Pathologically confirmed invasive breast adenocarcinoma with documented ER\u002FPR\u002FHER2 status and radiographic evidence of distant metastatic or recurrent disease\n* COHORT 1 ONLY: Radiographic evidence of distant metastatic disease (using 7th edition American Joint Committee on Cancer \\[AJCC\\] criteria) with two discrete sites of measurable disease\n* COHORTS 2 \\& 3 ONLY: Radiographic evidence of distant metastatic or recurrent disease (using 8th edition AJCC criteria) with at least one site of measurable disease\n* Prior therapies:\n\n  * Patients with ER\u002FPR positive, HER2 negative breast cancer must have progressed through at least one prior cytotoxic regimen for advanced disease and no longer be candidates for standard endocrine therapy or combination of endocrine therapy with other agents such as CDK4\u002F6 inhibitors\n  * Patients with HER2 positive breast cancer irrespective of ER\u002FPR status must have received or no longer be candidates for HER2 directed therapy with trastuzumab or pertuzumab\n  * Patients with ER\u002FPR\u002FHER2 negative breast cancer must have progressed through at least one prior cytotoxic regimen for advanced disease\n* COHORT 1: At least one site of recurrent\u002Fmetastatic disease that measures \\> 1 cm in greatest dimension (\\> 2 cm for lung lesions) and is amenable to safe percutaneous intratumoral administration of MV-s-NAP as determined by an interventional radiologist\n* COHORTS 2 \\& 3 ONLY: At least 1 site of recurrent\u002Fmetastatic disease measuring \\> 1 cm in greatest dimension \\[\\> 2 cm for lung lesions\\] (Note that if the lesion injected in cycle 1 is not amenable to re-injection, another lesion could be selected for injection\n* Absolute neutrophil count (ANC) \\>= 1500\u002FuL (=\\\u003C 7 days prior to registration)\n* Platelets (PLT \\>= 100,000\u002FuL) (=\\\u003C 7 days prior to registration)\n* Total bilirubin =\\\u003C institutional upper limit of normal (=\\\u003C 7 days prior to registration)\n* Aspartate aminotransferase (AST) =\\\u003C 2 x upper limit of normal (ULN) (=\\\u003C 7 days prior to registration)\n* Creatinine =\\\u003C 1.5 x ULN (=\\\u003C 7 days prior to registration)\n* Hemoglobin \\>= 9.0 g\u002FdL (=\\\u003C 7 days prior to registration)\n* Negative pregnancy test done =\\\u003C 7 days prior to registration (for women of childbearing potential only)\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2\n* Ability to provide informed written consent\n* Willingness to return to the Mayo Clinic enrolling institution for follow-up\n* Willingness to provide biologic samples for correlative research purposes\n* Life expectancy \\>= 12 weeks\n* Concomitant administration of a bone modifying agent (e.g., zoledronic acid or denosumab) is permitted for the prevention or management of skeletal related events in patients with bone metastases and documentation of tolerability with prior exposures\n\nExclusion Criteria:\n\n* Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy\n* Clinical or radiographic suspicion of impending visceral crisis due to invasion or compression by tumor\n* Active infection =\\\u003C 5 days prior to registration\n* History of other malignancy =\\\u003C 5 years except for non-melanoma skin cancer or carcinoma in situ of the cervix\n* Any of the following prior therapies:\n\n  * Chemotherapy =\\\u003C 3 weeks prior to registration\n  * Immunotherapy =\\\u003C 4 weeks prior to registration\n  * HER2 directed therapy =\\\u003C 3 weeks prior to registration\n  * Targeted therapy =\\\u003C 2 weeks prior to registration (e.g., CDK4\u002F6 inhibitors, everolimus)\n  * Investigational agent =\\\u003C 4 weeks prior to registration\n  * Any viral or gene therapy prior to registration\n* Failure to fully recover from acute, reversible effects of prior systemic therapy regardless of interval since last treatment\n* New York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia \\[SVT\\])\n* Untreated or progressive central nervous system (CNS) metastases\n\n  * NOTE: Patients with a history of treated brain metastases (surgical resection, whole brain radiation, and\u002For stereotactic radiosurgery) are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including \\\u003C 28 days of study entry\n* Standing requirement for blood product support\n* Human immunodeficiency virus (HIV) positive test result or history of other immunodeficiency\n* History of organ transplantation\n* History of chronic hepatitis B or C\n* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration \\[FDA\\]-approved indication and in the context of a research investigation)\n* Any concurrent medications that the principal investigator determines could interfere with the trial\n* Treatment with oral\u002Fsystemic corticosteroids, with the exception of topical or inhaled steroids\n* Exposure to household contacts =\\\u003C 15 months old or household contact with known immunodeficiency\n* Allergy to measles vaccine or history of severe reaction to prior measles vaccination\n* History of receiving the measles vaccination with the \"killed vaccine\" between 1963-1967 without subsequent re-immunization (2 doses) with the active, live vaccination.\"","18 Years",{"count":110,"type":22},54,"INTERVENTIONAL",[113],"PHASE1","This phase I trial investigates the side effects and best dose of using a modified measles virus, MV-s-NAP, in treating patients with invasive breast cancer that has spread to other places in the body (metastatic). Both the unmodified vaccination measles virus (MV-Edm) and this modified virus (MV-s-NAP) have been shown to multiply in and destroy breast cancer cells in the test tube and in research mice. MV-s-NAP has been altered by having an extra gene (piece of deoxyribonucleic acid \\[DNA\\]) so that virus can make a protein called helicobacter pylori neutrophil activating protein (NAP) which is normally expressed in inflammatory reactions. Monitoring blood, urine, tissue, and throat swab samples, and using imaging tests may help to determine whether MV-s-NAP has any impact on the amount of disease present in metastatic breast cancer patients.",[116,37,117,118,78],"Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Adenocarcinoma","Recurrent Breast Carcinoma","2026-06-16",{"date":121,"type":92},"2026-06-17",{"date":123,"type":92},"2020-09-23",{"date":125,"type":22},"2027-08-15",{"name":127,"class":99},"Mayo Clinic",1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":111,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":155},"100317923","phase-3-s1501-dual-observational-and-randomized-cohort-study-of-patients-with-metastatic-her-2-breast-cancer-at-risk-of-cardiac-toxicity-100317923","NCT03418961","S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity","Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity","Inclusion Criteria:\n\n* STEP 1 REGISTRATION\n\nPatients must:\n\n1. Have metastatic breast cancer, AND\n2. Be initiating within 11 calendar days of Step 1 Registration OR be continuing trastuzumab-based HER-2 targeted therapy without concurrent anthracyclines, AND\n3. Be receiving the trastuzumab-based HER-2 targeted therapy for metastatic disease in first, second, third-, or fourth-line setting. Patients may have brain metastasis. There is no limit for number of doses of HER-2 targeted therapy prior to registration.\n\nExamples of eligible HER-2 targeted therapy:\n\n* Trastuzumab or a trastuzumab biosimilar\n* Trastuzumab + chemotherapy or hormonal therapy\n* Trastuzumab + other HER-2 targeted agent with or without chemotherapy (such as pertuzumab, lapatinib, and tucatinib)\n* Ado-trastuzumab (Kadcyla®)\n* Fam-trastuzumab deruxtecan (Enhertu) NOTE: Patients on lapatinib without trastuzumab are not eligible. Planned treatment with concurrent HER-2 targeted therapy and anthracyclines is not permitted.\n\n  * Patients must be at increased risk for cardiotoxicity defined by at least one of the following:\n\n    1. Previous anthracycline exposure OR\n    2. 1 or more of the following risk factors for heart disease:\n\n       * LVEF 50-54% by local ECHO read\\*\n       * Age ≥ 65\n       * BMI ≥ 30 kg\u002Fm2\n       * Current or prior anti-hypertensive therapy\n       * Diagnosis of coronary artery disease (CAD)\n       * Diagnosis of diabetes mellitus\n       * Diagnosis of atrial fibrillation\u002Fflutter Note: ECHO can be performed at any time prior to registration with the most recent being sent.\n  * Patients must not have taken within 21 days prior to Step 1 Registration, be currently taking at the time of Step 1 Registration or planning to take once registered to Step 1 a beta blocker, ARB, or ACE inhibitor, in order to be randomized (Arms 1 and 2).\n\nPatients enrolling in the observational cohort (Arm 3) must be currently taking a beta blocker, ARB, or ACE inhibitor at the time of Step 1 Registration.\n\n* Patients must have a Zubrod Performance status of 0-2\n* Patients must have a complete physical examination and medical history within 28 days prior to registration\n* Patients must have LVEF \\>= 50% echocardiogram (2D or 3D) within 28 days prior to registration. The echocardiogram must be obtained from a S1501 validated ECHO laboratory (lab) and submitted for central review by the S1501 ECHO core lab.\n\nIf a 3D echocardiogram is performed at baseline, sites must ensure that standard 2D images, including 40chamber and 2-chamber views, are also obtained and submitted at subsequent timepoints.\n\nAll follow-up echocardiograms (every 12 weeks) must be performed using 2D imaging to allow for standardized assessments. Follow-up scans must be completed at a site that can provide 2D images per protocol requirements. The echocardiograms cannot be submitted for central read until after Step 1 registration is complete.\n\n* Patients must have adequate hepatic function as evidenced by all of the following within 28 days prior to registration:\n\n  * Serum bilirubin \\\u003C 3.0 x institutional upper limit of normal (IULN)\n  * Serum glutamic oxaloacetic transaminase (SGOT)\u002Faspartate aminotransferase (AST) and serum glutamic pyruvic transaminase (SGPT)\u002Falanine aminotransferase (ALT) \\\u003C 5.0 x IULN\n* Patients must not be dialysis dependent\n* No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer on active surveillance, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years\n* Patients must not be pregnant or nursing due to potential fetal or nursing infant harm; women\u002Fmen of reproductive potential must have agreed to use an effective contraceptive method, a woman is considered to be of \"reproductive potential\" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, \"effective contraception\" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he\u002Fshe is responsible for beginning contraceptive measures\n* Patients must be willing to submit blood specimens\n* Sites must seek additional patient consent for the future use of specimens\n* Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines\n* For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and CIRB regulations.\n* As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\n* STEP 2 REGISTRATION (Randomization)\n* Patients must not be registered to step 2 until confirming via RAVE EDC that the patient's LVEF by echocardiogram was \\>= 50% by central review. Patients must be registered within 21 calendar days of submission of the ECHO study\u002F\n* Site must verify that there is no known change in the step 1 eligibility since initial registration",{"count":137,"type":22},491,[139],"PHASE3","This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.",[142,143,144,118,78],"Cardiotoxicity","HER2\u002FNeu Positive","Metastatic Malignant Neoplasm in the Brain","2025-10-03",{"date":147,"type":92},"2025-10-08",{"date":149,"type":92},"2017-11-01",{"date":151,"type":22},"2027-09-15",{"name":153,"class":154},"SWOG Cancer Research Network","NETWORK",590]